NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
RA’ANANA, Israel and NEW YORK, May 10, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology with a focus on uro-oncology, announced today the closing of its initial public offering on May 9, 2017 of an aggregate of 5,144,378 ordinary shares at a public offering price of $13.00 per share, including the exercise in full of the underwriters’ option to purchase an additional 671,005 shares, resulting in gross proceeds of approximately $66.9 million.
Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. acted as co-managers for the offering.
A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on May 3, 2017. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at [email protected]; or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About UroGen Pharma Ltd.
UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
CONTACT: Gary Titus, UroGen Pharma Ltd. 689 Fifth Avenue, 14th Floor New York, NY 10022 [email protected] 646-768-9531 Stephanie Carrington, ICR, Inc. 685 Third Avenue, 2nd Floor New York, NY 10017 [email protected] 646-277-1282
